YCCI/Church Street Research Unit (CSRU)
Welcome,         Profile    Billing    Logout  
 0 Trials 
4 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Damsky, William
NCT05696795: Janus Kinase Inhibition in Sarcoidosis

Completed
2
10
US
Abrocitinib 200 mg
Yale University, Pfizer
Sarcoidosis
04/25
04/25
NCT05650736: Janus Kinase Inhibition in Granuloma Annulare

Active, not recruiting
2
10
US
Abrocitinib 200 mg
William Damsky, Yale University, Pfizer
Granuloma Annulare
05/24
07/25
NCT06725264: Tyrosine Kinase 2 (TYK2) for GA and CS

Withdrawn
2
10
US
Deucravacitinib, Sotyktu
Yale University, Bristol-Myers Squibb
Sarcoidosis, Granuloma Annulare
06/26
06/26
NCT05580042: Study to Evaluate the Safety and Tolerability of AC-1101 Topical Gel in Patients with Granuloma Annulare

Completed
1
13
US
AC-1101, Tofacitinib Topical Gel 2%, AC-1101 gel
TWi Biotechnology, Inc.
Granuloma Annulare
11/23
11/23
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Damsky, William
NCT05696795: Janus Kinase Inhibition in Sarcoidosis

Completed
2
10
US
Abrocitinib 200 mg
Yale University, Pfizer
Sarcoidosis
04/25
04/25
NCT05650736: Janus Kinase Inhibition in Granuloma Annulare

Active, not recruiting
2
10
US
Abrocitinib 200 mg
William Damsky, Yale University, Pfizer
Granuloma Annulare
05/24
07/25
NCT06725264: Tyrosine Kinase 2 (TYK2) for GA and CS

Withdrawn
2
10
US
Deucravacitinib, Sotyktu
Yale University, Bristol-Myers Squibb
Sarcoidosis, Granuloma Annulare
06/26
06/26
NCT05580042: Study to Evaluate the Safety and Tolerability of AC-1101 Topical Gel in Patients with Granuloma Annulare

Completed
1
13
US
AC-1101, Tofacitinib Topical Gel 2%, AC-1101 gel
TWi Biotechnology, Inc.
Granuloma Annulare
11/23
11/23

Download Options